Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review

Pure red cell aplasia (PRCA) is a possible complication after allogeneic hematopoietic stem cell transplantation (HSCT) with major ABO incompatibility. Patients experience delayed engraftment of the erythroid series, with prolonged transfusion-dependent anemia and iron overload. We performed a revis...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2024-07, Vol.14, p.1386670
Main Authors: Metafuni, Elisabetta, Busnego Barreto, Maria Teresa, Valentini, Caterina Giovanna, Giammarco, Sabrina, Limongiello, Maria Assunta, Sorà, Federica, Bianchi, Maria, Massini, Giuseppina, Piccirillo, Nicola, Putzulu, Rossana, Frioni, Filippo, Bacigalupo, Andrea, Teofili, Luciana, Chiusolo, Patrizia, Sica, Simona
Format: Article
Language:English
Subjects:
daratumumab
HSCT
isohemagglutinins
Oncology
plasma-exchange
PRCA
rituximab
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pure red cell aplasia (PRCA) is a possible complication after allogeneic hematopoietic stem cell transplantation (HSCT) with major ABO incompatibility. Patients experience delayed engraftment of the erythroid series, with prolonged transfusion-dependent anemia and iron overload. We performed a revision of the most recent literature about post-HSCT PRCA treatment procedures. Moreover, we conducted a retrospective study, over the last 13-years, which included all consecutive major ABO mismatched HSCT performed in our unit, with the aim to assess PRCA incidence, risk factors, and response to different treatments. Overall, 194 patients received a major ABO mismatched transplant from 2010 to 2022. For each patient, data about demographic and transplant characteristics, engraftment, blood transfusion, and possible treatment received were collected. The literature review returned 23 eligible papers on PRCA treatment, with high success rate using plasma-exchange (PEX) and immunoadsorption procedures, daratumumab, and eltrombopag. Our study identified a total of 24 cases of PRCA. Among risk factors for PRCA development, we have found older recipient age (p=0.01), high pre-HSCT IgG and IgM IHA titer (p
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2024.1386670